Café

© 2026 Longbridge｜Terms of Service Privacy Policy

TScan Therapeutics

TCRX

----

OverviewOverview NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

TScan Therapeutics (TCRX)

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients wit...

Open: --
High: --
Low: --
Prev. Close: --
Volume: --
Turnover: --
Avg Price: --
Bid/Ask Ratio: --
Amplitude: --
52wk High: --
Volume Ratio: --
Turnover Ratio: --

52wk Low: --
Float Mkt Cap: --
Market Cap: --
P/E^TTM: --
P/E^Dynamic: --
P/E^Static: --
EPS^TTM: --
EPS^Dynamic: --
EPS^Static: --
BVPS: --
P/B: --
Circulating Supply: --
Dividend Yield^TTM: --
Dividend^TTM: --
Shares: --
Min lot size: --
Currency: --

TScan Therapeutics Analyst Rating

Forecast & Rating

Sep 8, 2026

Price forecast

$2.67722.54%

Forecast & RatingHold

6analysts

Strong buy16.67%
Buy0.00%
Hold83.33%
Sell0.00%
Strong sell0.00%

Strong buy: 1
Buy: 0
Hold: 5
Sell: 0
Strong sell: 0

News

PUBT · Sep 11 at 12:02 PM
TScan rolls out retention plan with $822,000 cash award for CEO Gavin MacBeath
Weekly Review · Sep 5 at 08:11 AM
Weekly Recap | TScan Therapeutics -48.04%, reorganisation pivots to in vivo cell therapy
biopharmadive · Sep 4 at 04:23 PM
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
benzinga_article · Sep 2 at 05:06 PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga_article · Sep 2 at 04:01 PM
Crude Oil Moves Higher; US Factory Orders Rise In July